Type 2 Diabetes Mellitus Completed Phase 3 Trials for Insulin Aspart (DB01306)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00032487Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)Treatment
NCT00434954Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 DiabetesTreatment
NCT01474538Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump TherapyTreatment
NCT01850615Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 DiabetesTreatment
NCT03268005Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 DiabetesTreatment
NCT02762578Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 DiabetesTreatment
NCT01513590A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 DiabetesTreatment
NCT01819129Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 DiabetesTreatment
NCT01059812A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 DiabetesTreatment
NCT01009580Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 DiabetesTreatment
NCT02906917A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment IntensificationTreatment
NCT02648217Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After RamadanTreatment
NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes MellitusTreatment
NCT00476437Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.Treatment
NCT00504673Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 DiabetesTreatment
NCT00598793Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD TherapyTreatment
NCT01045707Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 DiabetesTreatment
NCT01045447Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 DiabetesTreatment
NCT01365507Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing RegimensTreatment
NCT01467323Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 DiabetesTreatment
NCT01388361Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and MetforminTreatment
NCT00612599Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 DiabetesTreatment
NCT01520818Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With DiabetesTreatment
NCT01520753Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 DiabetesTreatment
NCT01527539Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 DiabetesTreatment
NCT01650129Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 DiabetesTreatment
NCT01467375Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 DiabetesTreatment
NCT00617565Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 DiabetesTreatment
NCT00564668Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 DiabetesTreatment
NCT00082407Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and MetforminTreatment
NCT00000620Action to Control Cardiovascular Risk in Diabetes (ACCORD)Prevention
NCT00627445Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 DiabetesTreatment
NCT00605020Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 DiabetesTreatment
NCT01713530A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime InsulinTreatment
NCT01680341Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin GlargineTreatment
NCT02100475A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further IntensificationTreatment
NCT01272193Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 DiabetesTreatment
NCT00280046Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 DiabetesTreatment
NCT00313001Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.Treatment
NCT00318786Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 DiabetesTreatment
NCT00184574Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 DiabetesTreatment
NCT00184600Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 DiabetesTreatment
NCT00097877Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 DiabetesTreatment
NCT00097084Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 DiabetesTreatment
NCT00097279Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 DiabetesTreatment
NCT00106366Comparison of Insulin Detemir With Insulin Glargine in Type 2 DiabetesTreatment
NCT01814137A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice DailyTreatment
NCT00600626Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 DiabetesTreatment
NCT00972283Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 DiabetesTreatment
NCT00309244Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-upPrevention
NCT00151697LANN-study: Lantus, Amaryl, Novorapid, Novomix StudyTreatment